{"id":"689317a3a08b","type":"article","url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","title":"Sacubitril/valsartan of enalapril bij acuut gedecompenseerd HF: PIONEER-HF klinische uitkomsten","title_en":"Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["answer-hf","sacubitril-valsartan"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.118.039331","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.118.039331","authors":["David A Morrow","Eric J Velazquez","Adam D DeVore","Akshay S Desai","Carol I Duffy","Andrew P Ambrosy","Yared Gurmu","Kevin McCague","Ricardo Rocha","Eugene Braunwald"],"significance":7,"published":"2019-05-07","source_date":"2019-05-07","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/arni-farmacologie/","https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"This PIONEER-HF clinical outcomes analysis confirmed that sacubitril-valsartan initiated during heart failure hospitalization is safe with consistent benefits on heart failure events, supporting the in-hospital ARNI initiation strategy.","created":"2026-07-03T10:27:55Z","updated":"2026-07-03T13:27:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"PIONEER-HF klinische uitkomstanalyse die sacubitril/valsartan bevestigt als veilig en effectief bij in-hospital gestarte HF-patiënten.","abstract_original":""}